Successful Combination of Olaparib and 225Ac-Dotatate in a Patient with Neuroendocrine Tumor G3 and BRCA Mutation

Successful Combination of Olaparib and 225Ac-Dotatate in a Patient with Neuroendocrine Tumor G3 and BRCA Mutation

Based on the results of the NETTER-1 trial, peptide receptor radionuclide therapy with Lutetium-177 (177Lu) – DOTATATE is authorized for the treatment of neuroendocrine tumors (NET) grade 1 (G1) and grade 2 (G2) of the intestine. After the failure of 177Lu-DOTATATE therapy, targeted alpha-particle t...

Full description

Bibliographic Details
Main Authors: Anke Kröcher, Gunnar Folprecht, Robert Winzer, Mildred Sergon, Martin Bornhäuser, Jörg Kotzerke, Claudia Brogsitter
Format: Article
Language:English
Published: Karger Publishers 2023-10-01
Series:Case Reports in Oncology
Subjects:
brca mutation
olaparib
targeted alpha-particle therapy
neuroendocrine tumor
peptide receptor radionuclide therapy
Online Access:https://beta.karger.com/Article/FullText/533198

Internet

https://beta.karger.com/Article/FullText/533198

Similar Items